Patents by Inventor Christine KUETTEL

Christine KUETTEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250059298
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: July 26, 2024
    Publication date: February 20, 2025
    Inventors: Stephan GASSER, Thomas HOFER, Teemu Tapani JUNTTILA, Christian KLEIN, Christine KUETTEL, Jenny Tosca THOM, Pablo UMAÑA
  • Patent number: 12049515
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: July 30, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stephan Gasser, Thomas Hofer, Teemu Tapani Junttila, Christian Klein, Christine Kuettel, Jenny Tosca Thom, Pablo Umaña
  • Publication number: 20220017637
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: June 22, 2021
    Publication date: January 20, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Thomas HOFER, Teemu Tapani JUNTTILA, Christian KLEIN, Christine KUETTEL, Jenny Tosca THOM, Pablo UMAÑA